Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
A multicenter team of researchers within the NIH-funded Cardiothoracic Surgical Trials Network (CTSN), led by Icahn School of Medicine at Mount Sinai, have found end-stage heart failure patients who receive a surgically implanted left ventricular assist device (LVAD) heart pump may also benefit from a single dose of millions of powerful cells injected directly into their heart during surgery.
The CTSN, whose Data and Clinical Coordinating Center is at Icahn School of Medicine at Mount Sinai, conducted the clinical trial in collaboration with the Cardiovascular Cell Therapy Research Network.
Allogeneic mesenchymal precursor cells (MPCs), are a subpopulation of adult mesenchymal stem cells, which when harvested from a healthy donor's bone marrow can be selected and expanded in the laboratory into hundreds of millions of MPCs.
At the American Heart Association Scientific Sessions 2013, Icahn School of Medicine at Mount Sinai's research team presented the new findings for this novel, first-ever randomized, double-blinded multicenter trial assessing the safety and efficacy of injecting a single dose of 25 million MPCs directly into the heart muscle of advanced heart failure patients receiving an LVAD for either bridge-to-transplant or as a destination therapy.
Study results show one dose of the MPC therapy may contribute to improved heart muscle recovery in advanced heart failure patients who received an LVAD. In their study, researchers reported that 50 percent of patients who received MPCs were able to tolerate temporarily turning down their LVAD heart pump, compared to 20 percent of the placebo patients. In addition, no patients developed serious side effects that may be associated with the stem cell injections.
"These clinical trial results provide important data about the safety and potential efficacy of a single MPC injection at the time of LVAD implantation," says the study's lead author Deborah D. Ascheim, MD, Associate Professor of Health Evidence and Policy and Cardiology at Icahn School of Medicine at Mount Sinai, who serves as Co-Director of the Data and Clinical Coordinating Center based at Mount Sinai for the NIH-sponsored Cardiothoracic Surgical Trials Network (CTSN) who conducted the clinical trial study.
"These mesenchymal precursor cells have shown their potential to safely facilitate early heart tissue repair in advanced heart failure. We look forward to investigating the benefits of this cell therapy further," says Dr. Ascheim.
The thirty LVAD patients enrolled in the clinical trial were randomized 2:1 at 11 clinical sites to evaluate the single dose injection of MPCs. Patients were assigned to either receive an injection of 25 million MPCs, or a placebo. All patients were followed until a heart transplant was received or until one-year.
The CTSN has eight core clinical centers across the country. It's Data and Clinical Coordinating Center, based at Icahn School of Medicine at Mount Sinai, leads each of its clinical trial's design, methodologies, ethical research concerns, study data, analysis, and data reporting.
The company that makes this experimental MPC therapy is Mesoblast, Inc.
This study was presented at the AHA Scientific Sessions as a Clinical Science Special Report (Abstract 19673): Intramyocardial Injection of Allogeneic Mesenchymal Precursor Cells in Left Ventricular Assist Device Patients.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Heart Disease category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
The Mount Sinai Hospital / Mount Sinai School of M. "Single dose of stem cell therapy during surgery may improve new LVAD patients' heart function." Medical News Today. MediLexicon, Intl., 22 Nov. 2013. Web.
23 Apr. 2014. <http://www.medicalnewstoday.com/releases/269112>
The Mount Sinai Hospital / Mount Sinai School of M. (2013, November 22). "Single dose of stem cell therapy during surgery may improve new LVAD patients' heart function." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/269112.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT is the registered trade mark of MediLexicon International Limited.